home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2787.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
46 lines
Document 2787
DOCN M94A2787
TI Beneficial effects of intravenous immunoglobulins (IVIg) in the
treatment of ARC patients.
DT 9412
AU Saint-Marc T; Berra N; Perraud P; Livrozet JM; Fournier F; Touraine JL;
Transplantation & Clinical Immunology Unit, Hop. E. Herriot,; Lyon,
France.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):225 (abstract no. PB0330). Unique
Identifier : AIDSLINE ICA10/94369788
AB OBJECTIVE: Evaluation of the clinical and immunological effects of
systematic and regular infusions of immunoglobulins in adult patients
with a severe deficiency of cell-mediated immunity and of antibody
production related to HIV infection. METHODS: Starting in January 1991,
44 ARC patients were enrolled in a prospective clinical trial. The
patients were randomized to receive either no additional treatment or a
monthly infusion of IVIg (Endobulin, ImmunoFrance) at the dose of
200mg/kg for 24 months. The patients were evaluated every 4 weeks for
clinical examination and routine laboratory tests and every 12 weeks for
cell surface markers (CD4, CD8, ...). The clinical objectives were to
determine whether IVIg prevented the occurrence of an AIDS-defining
opportunistic infection (OI) or Kaposi Sarcoma and whether IVIg had an
effect on survival. RESULTS: 39 patients were evaluable for analysis.
There were a total of 14 patients progressing to a first AIDS-defining
OI, 4 in the IVIg group and 10 in the control group. IVIg significantly
reduced the incidence of OI (p < 0.05). 4 patients developed Kaposi
Sarcoma, 3 in the treated group and 1 in the control group (no
statistical difference). 3 deaths occurred in the treated group and 6 in
the control group. There were a significant difference in the CD4+ and
CD8+ cell count with an increase in CD8+ and a stabilisation in CD4+ in
the treated group while a decrease of both CD4+ and CD8+ cells was
noticed in the control group. CONCLUSION: These results confirm our
previous finding of a significant benefit of IVIg in AIDS patients and
they show that ARC patients develop less infections. IVIg delays
progression of the disease and of death in HIV-infected patients.
DE Adult AIDS-Related Complex/MORTALITY/*THERAPY AIDS-Related
Opportunistic Infections/EPIDEMIOLOGY/PREVENTION & CONTROL Human
Immunoglobulins, Intravenous/*THERAPEUTIC USE Leukocyte Count
Prospective Studies Sarcoma, Kaposi's/EPIDEMIOLOGY/PREVENTION & CONTROL
T-Lymphocytes, Cytotoxic Treatment Outcome T4 Lymphocytes CLINICAL
TRIAL MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).